Elevated VEGF concentrations in ascites and serum predict adverse prognosis in ovarian cancer

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
   Google Scholar
• Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 2005;5:355–66.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415–28.
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519–29.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248–59.
   PubMed Web of Science ®Google Scholar
• Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19:3–10.
   PubMed Web of Science ®Google Scholar
• Huang KJ, Sui LH. The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol 2012; 29:318–23.
   PubMed Web of Science ®Google Scholar
• Zhao RW, Yang SH, Cai LQ, Zhang J, Wang J, Wang ZH. [Roles of vascular endothelial growth factor and platelet-derived growth factor in lymphangiogenesis in epithelial ovarian carcinoma.]. Zhonghua Fu Chan Ke Za Zhi 2009; 44:760–4.
   PubMedGoogle Scholar
• Sinn BV, Darb-Esfahani S, Wirtz RM, Faggad A, Weichert W, Buckendahl AC, Noske A, Muller BM, Budczies J, Sehouli J, Braicu EI, Dietel M, Denkert C. Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue. Virchows Arch 2009;455:461–7.
   PubMed Web of Science ®Google Scholar
• Ueda M, Hung YC, Terai Y, Kanda K, Kanemura M, Futakuchi H, Yamaguchi H, Akise D, Yasuda M, Ueki M. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res 2005;11:3225–32.
   PubMed Web of Science ®Google Scholar
• Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15:290–8.
   PubMed Web of Science ®Google Scholar
• Plate K. From angiogenesis to lymphangiogenesis. Nat Med 2001;7:151–2.
   PubMed Web of Science ®Google Scholar
• Han FH, Li HM, Zheng DH, He YL, Zhan WH. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol 2010; 36:1172–9.
   PubMed Web of Science ®Google Scholar
• Gu Y, Qi X, Guo S. Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases. Clin Exp Metastasis 2008;25:717–25.
   PubMed Web of Science ®Google Scholar
• Garcia EA, Simoes K, Wakamatsu A, Ressio RA, Alves VA, Longatto-Filho A, Camargo RS. Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions. Endocr Pathol 2010; 21:101–7.
   PubMed Web of Science ®Google Scholar
• Ma DM, Xu YP, Zhu L. Expression of vascular endothelial growth factor C correlates with a poor prognosis based on analysis of prognostic factors in patients with cervical carcinomas. J Obstet Gynaecol Res 2011;37:1519–24.
   PubMed Web of Science ®Google Scholar
• Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004;101:1364–74.
   PubMed Web of Science ®Google Scholar
• Woopen H, Sehouli J. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res 2009;29:3353–9.
   PubMed Web of Science ®Google Scholar
• Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. J Reprod Med 1996;41:140–2.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer 2001;11:277–82.
   PubMed Web of Science ®Google Scholar
• Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, Massobrio M, Van Der Zee AG, Vergote I, Katsaros D. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003;21:1035–43.
   PubMed Web of Science ®Google Scholar
• Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, van der Zee AG, Vergote I, Diamandis EP. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63:807–11.
   PubMed Web of Science ®Google Scholar
• Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011;11:210.
   PubMed Web of Science ®Google Scholar
• Marth C, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Doppler W, Daxenbichler G. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 2004;191:1598–605.
   PubMed Web of Science ®Google Scholar
• Hefler L, Mayerhofer K, Nardi A, Reinthaller A, Kainz C, Tempfer C. Serum soluble Fas levels in ovarian cancer. Obstet Gynecol 2000;96:65–9.
   PubMed Web of Science ®Google Scholar
• Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB, Reinthaller A. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 2006;103:512–7.
   PubMed Web of Science ®Google Scholar
• Koh SC, Khalil R, Lim FK, Ilancheran A, Choolani M. The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost 2006;12:3–8.
   PubMed Web of Science ®Google Scholar
• Modugno F. Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol Oncol 2003;91:15–31.
   PubMed Web of Science ®Google Scholar
• Alitalo A, Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2011;31: 4499–508.
   PubMed Web of Science ®Google Scholar
• He XW, Yu X, Liu T, Yu SY, Chen DJ. Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice. Chin Med J (Engl) 2008;121:439–44.
   PubMed Web of Science ®Google Scholar
• Sangoi AR, McKenney JK, Dadras SS, Longacre TA. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study. Am J Surg Pathol 2008;32:261–8.
   PubMed Web of Science ®Google Scholar
• Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS, Alitalo K, Koh GY. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res 2008;68:1100–9.
   PubMed Web of Science ®Google Scholar
• Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192–8.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J 2002;16:922–34.
   PubMed Web of Science ®Google Scholar
• Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, van Trappen P, Cox G, Harris AL, Jackson DG. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002;62:1315–20.
   PubMed Web of Science ®Google Scholar
• Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003;162:1951–60.
   PubMed Web of Science ®Google Scholar
• Ohno F, Nakanishi H, Abe A, Seki Y, Kinoshita A, Hasegawa Y, Tatematsu M, Kurita K. Regional difference in intratumoral lymphangiogenesis of oral squamous cell carcinomas evaluated by immunohistochemistry using D2-40 and podoplanin antibody: an analysis in comparison with angiogenesis. J Oral Pathol Med 2007;36:281–9.
   PubMed Web of Science ®Google Scholar
• Mello MF, Costa AF, Freitas LL, Soares AB, Araujo VC, Tincani AJ, Martins AS, Altemani A. Lymphatic vessel density and expressions of lymphangiogenic growth factors in salivary carcinomas. Neoplasma 2011;58:331–6.
   PubMed Web of Science ®Google Scholar
• Möbius C, Freire J, Becker I, Feith M, Brucher BL, Hennig M, Siewert JR, Stein HJ. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg 2007;31:1768–72; discussion 73–4.
   PubMed Web of Science ®Google Scholar
• Gou HF, Chen XC, Zhu J, Jiang M, Yang Y, Cao D, Hou M. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res 2011;30:14.
   PubMed Web of Science ®Google Scholar
• Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 2006; 95:1611–25.
   PubMed Web of Science ®Google Scholar